Aldeyra Therapeutics (ALDX)
(Delayed Data from NSDQ)
$4.81 USD
-0.18 (-3.61%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $4.80 -0.01 (-0.21%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ALDX 4.81 -0.18(-3.61%)
Will ALDX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALDX
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
ALDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock?
Are Medical Stocks Lagging Amgen (AMGN) This Year?
Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock?
Other News for ALDX
ALDX Gains Orphan Status in Europe for Vision Loss Treatment | ALDX Stock News
Aldeyra receives orphan designation for ADX-2191 from EMA
Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ...
Commit To Buy Aldeyra Therapeutics At $2.50, Earn 28.4% Annualized Using Options
Aldeyra (ALDX) Resubmits Reproxalap NDA to FDA